Advanced Filters
noise

Oststeinbek, Germany Clinical Trials

A listing of Oststeinbek, Germany clinical trials actively recruiting patients volunteers.

Found 286 clinical trials
A Adam Octavian, MD

Abbott DBS Post-Market Study of Outcomes for Indications Over Time

The purpose of this international study is to evaluate long-term safety and effectiveness of Abbott deep brain stimulation (DBS) systems for all indications, including Parkinson's disease, essential tremor or other disabling tremor and dystonia.

years of age All Phase N/A
G Gema Maria Garcia Ledo

Met Non Small Cell Cancer Registry (MOMENT)

The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time. The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, …

years of age All Phase N/A
B Benedikt Koell, MD

Outcomes of Patients tReated wIth Mitral Transcatheter Edge-to-edge Repair for Primary Mitral Regurgitation Registry

This multinational, non-interventional, investigator-initiated, retrospective study aims to investigate outcomes of patients, who underwent mitral valve transcatheter edge-to-edge repair (M-TEER) for primary mitral regurgitation (PMR).

18 years of age All Phase N/A
T Thomas Schmitz, Dr.

MiCLASP Post Market Clinical Follow-Up (PMCF) Study

This is a postmarket clinical follow up study on the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System and the Edwards PASCAL Precision Transcatheter Valve Repair System in transcatheter mitral valve repair.

18 years of age All Phase N/A

Post-Market Clinical Follow Up Study With Navitor Valve

Evaluation of the safety and performance of the Navitor TAVI System in a Global Study

18 - 100 years of age All Phase N/A
J Jonas Pausch, MD

PROMISE: Percutaneous peRipheral cannulatiOn for Minimally-InvaSive Heart Valve surgEry

In addition to conventional heart valve surgery (HVS) via full-sternotomy, which is still the most prevalent therapeutic strategy to address valvular heart disease (VHD), minimally-invasive approaches evolved as safe alternatives, resulting in lower postoperative ventilation times, transfusion rates and shorter in-hospital stay. Femoral artery cannulation is traditionally performed via surgical …

18 years of age All Phase N/A
O Oleg Gluz, PD. Dr. med.

PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS

There is only limited data for premenopausal patients in general, as well as for differences in the use of OFS in the subgroups of pre- and perimenopausal patients, respectively. The WSG ADAPT trial data on the impact of postmenopausal status and/or use of OFS within 3-4 weeks endocrine induction therapy …

18 - 60 years of age Female Phase N/A

Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment

BERING-MELANOMA - designed as a prospective, longitudinal, non-interventional study - investigates real-world effectiveness, quality of life, safety and tolerability of encorafenib plus binimetinib in unresectable advanced or metastatic BRAF(Rapidly Accelerated Fibrosarcoma isoform B)-V600-mutant malignant melanoma after commercial availability of these two products in Germany, Austria and Switzerland. The study focusses …

18 years of age All Phase N/A

Tricuspid RegUrgitaTion Hamburg Cohort

Tricuspid regurgitation (TR) is frequent and has been directly related to high mortality rates. The pathophysiology of TR is mainly functional as it occurs predominantly in the context of left-sided heart disease, pulmonary hypertension, or atrial fibrillation. Surgery is currently the primary treatment option in patients with functional TR. However, …

18 years of age All Phase N/A

PASS of Paediatric Patients Initiating Selumetinib

Neurofibromatosis type 1 (NF1) is a rare, autosomal dominant genetic disorder that is caused by germline mutations in the NF1 tumour suppressor gene, which encodes the tumour suppressor protein neurofibromin 1. Plexiform neurofibromas (PN) are histologically benign nerve sheath tumours, which typically grow along large nerves and plexi. On 5 …

3 - 17 years of age All Phase N/A

Simplify language using AI